{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:27:48Z","timestamp":1789244868906,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To observe the clinical effect and adverse reactions of perampanel in the treatment of epilepsy in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis was performed on 83 children with epilepsy who were treated with perampanel in the Department of Pediatric Neurology, Second Affiliated Hospital of Xi'an Jiaotong University from April to August 2021. The treatment status, prognosis and adverse reactions were followed up. The effective rates of different age groups, different seizure types and epilepsy syndromes, and different treatment methods were statistically analyzed. The effective rate and adverse reactions of all patients were statistically analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall effective rate of perampanel in the treatment of epilepsy was 62.03%, and there was no significant difference in the effective rate of perampanel in the treatment of epilepsy in patients of different ages (<jats:italic>P<\/jats:italic> &amp;gt; 0.05). The effective rates of perampanel in the treatment of focal seizures and generalized seizures were 60.38% and 65.38%, and the effective rates of benign childhood epilepsy with centrotemporal spikes (BECT), BECT combined with electrical status epilepticus during sleep (ESES) and frontal lobe epilepsy (FLE) were 88.89, 72.73, and 66.67%. The effective rates of monotherapy and combination therapy were 88.88 and 58.57%, respectively. The above statistical differences were not statistically significant (<jats:italic>P<\/jats:italic> &amp;gt; 0.05). In addition, the adverse reaction rate of perampanel treatment was 16.45%, including irritability, drowsiness, dizziness, nausea, vomiting and abnormal liver function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Perampanel has a high efficiency and controllable adverse reactions in the treatment of childhood epilepsy. This drug can be used as a reliable choice for long-term use in the treatment of epilepsy in children.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.924057","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T06:23:01Z","timestamp":1658902981000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and adverse reactions of perampanel in the treatment of epilepsy in children"],"prefix":"10.3389","volume":"13","author":[{"given":"Dan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000503831","article-title":"The epidemiology of epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1684\/epd.2015.0751","article-title":"The natural history and prognosis of pilepsy","volume":"17","author":"Beghi","year":"2015","journal-title":"Epileptic Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12984-019-0605-x","article-title":"Neural stimulation systems for the control of refractory epilepsy: a review","volume":"16","author":"Bigelow","year":"2019","journal-title":"J Neuroeng Rehabil."},{"key":"B5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit."},{"key":"B6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/epi.14044","article-title":"Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: study 307","volume":"59","author":"Krauss","year":"2018","journal-title":"Epilepsia."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.neuron.2016.08.012","article-title":"Structural bases of noncompetitive inhibition of AMPA-subtype ionotropic glutamate receptors by antiepileptic drugs","volume":"91","author":"Yelshanskaya","year":"2016","journal-title":"Neuron."},{"key":"B8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/epi.14456","article-title":"Perampanel: does it have broad-spectrum potential?","volume":"60","author":"Potschka","year":"2019","journal-title":"Epilepsia."},{"key":"B9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.seizure.2019.12.024","article-title":"The efficacy of perampanel in young children with drug-resistant epilepsy","volume":"75","author":"Chang","year":"2020","journal-title":"Seizure"},{"key":"B10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/biom10030464","article-title":"Affiliations ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors","volume":"10","author":"Hanada","year":"2020","journal-title":"Biomolecules"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108528","article-title":"Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: post hoc analysis of open-label extension studies 307 and 332","author":"Resnick","year":"2022","journal-title":"Epilepsy Behav"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/epi.16548","article-title":"Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: experience from a national multicenter registry","volume":"61","author":"Toledano Delgado","year":"2020","journal-title":"Epilepsia."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1111\/epi.14522","article-title":"Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study","volume":"59","author":"Villanueva","year":"2018","journal-title":"Epilepsia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.seizure.2017.08.014","article-title":"Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: a UK national multicentre study","volume":"52","author":"Swiderska","year":"2017","journal-title":"Seizure."},{"key":"B15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.yebeh.2018.06.033","article-title":"Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: the first real-world evaluation in Asian pediatric neurology clinics","volume":"85","author":"Lin","year":"2018","journal-title":"Epilepsy Behav."},{"key":"B16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yebeh.2017.05.036","article-title":"Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome","volume":"74","author":"Auvin","year":"2017","journal-title":"Epilepsy Behav."},{"key":"B17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/epi4.12398","article-title":"Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures with newly diagnosed epilepsy or recurrence of epilepsy after a period of remission: the open-label Study 342 (FREEDOM Study)","volume":"5","author":"Yamamoto","year":"2020","journal-title":"Epilepsia Open."},{"key":"B18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/epi4.12445","article-title":"Perampanel in real-world clinical care of patients with epilepsy: Interim analysis of a phase IV study","volume":"6","author":"Wheless","year":"2020","journal-title":"Epilepsia Open."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108069","article-title":"Perampanel effectiveness and tolerability in patients with epilepsy at long-term follow-up","author":"Fernandes","year":"2021","journal-title":"Epilepsy Behav"},{"key":"B20","article-title":"Population pharmacokinetics and exposure-response analyses of adjunctive perampanel in pediatric patients with epilepsy","author":"Majid","year":"2018","journal-title":"The 72nd Annual Meeting of the American Epilepsy Society."},{"key":"B21","doi-asserted-by":"publisher","first-page":"108483","DOI":"10.1016\/j.yebeh.2021.108483","article-title":"A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy","volume":"126","author":"Maguire","year":"2022","journal-title":"Epilepsy Behav"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.924057\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T06:23:09Z","timestamp":1658902989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.924057\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,27]]},"references-count":21,"alternative-id":["10.3389\/fneur.2022.924057"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.924057","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,27]]},"article-number":"924057"}}